OBJECTIVE: To investigate whether low ERBB2 expression is associated with distinct clinicopathologic characteristics and prognosis among patients with hormone receptor (HR)-positive and triple-negative breast cancer (TNBC).DESIGN, SETTING, AND PARTICIPANTS: This co...
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found. In a clinical trial involving 512patientswith t...
HER2 antagonists remain the cornerstone of therapy for patients with HER2-positive breast cancer. This study introduces a novel small-molecule inhibitor of
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with t...
能确定新的事情的进展的一个主要作用也许用装载,好象它表明事件的认识特殊口气较不重要作用的无限数字。 [translate] aGenomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems. Genomic洞察到三倍消极和HER2正面乳腺癌里使用同基因的模型系统。 [translate] ...
1. What is the impact of HER2 levels in HER2-positive metastatic BC patients treated with standard therapy? 2. Is there room for targeting HER2-negative tumors with low HER2 expression (meaning cases with IHC score 1+ or 2+ not amplified by FISH)? Starting from the first question, the le...
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with ...
a breast cancer (HER2-positive) tissue section and a larger data set from a different cancer type (SCC), both data sets were profiled with different experimental platforms. Colocalization between Mø and T cells had already been shown in the SCC data set using antibody-based methods as well...
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with ...
The present study is a safety survey of patients with human epidermal growth factor receptor type 2-positive, chemotherapy-naive breast cancer treated with trastuzumab plus paclitaxel at the Saitama Cancer Center (Saitama, Japan) between April 2018 and March 2022. The expression of infusio...